- Trials with a EudraCT protocol (78)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
78 result(s) found for: Arterial embolism.
Displaying page 1 of 4.
EudraCT Number: 2014-003273-42 | Sponsor Protocol Number: 14AOI11 | Start Date*: 2014-12-23 | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Comparing a diuretic vascular filling in the initial management of acute pulmonary embolism with right ventricular dysfunction normotensive | |||||||||||||
Medical condition: acute pulmonary embolism with right ventricular dysfunction normotensive | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000816-96 | Sponsor Protocol Number: P160924 | Start Date*: 2020-04-27 |
Sponsor Name:AP-HP/ DRCI | ||
Full Title: A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism | ||
Medical condition: Intermediate high-risk acute pulmonary embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) SI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003997-33 | Sponsor Protocol Number: NOAH-AFNET6 | Start Date*: 2016-11-18 | |||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork] | |||||||||||||
Full Title: Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes | |||||||||||||
Medical condition: Atrial fibrillation (AF) is one cause of stroke. Stroke rate is increased in patients with atrial high rate episodes (AHRE, an early stage of AF) as well, even if stroke rates are lower when compa... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) BG (Completed) SE (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) GR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002298-25 | Sponsor Protocol Number: 20203331 | Start Date*: 2021-09-15 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP) | ||
Full Title: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001557-26 | Sponsor Protocol Number: CV185-048 | Start Date*: 2008-04-29 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial ... | |||||||||||||
Medical condition: Patients with atrial fibrillation and at least one additional risk factor for stroke who have failed or are unsuitable for vitamin K antagonist therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) SE (Completed) BE (Completed) DE (Completed) FI (Completed) ES (Completed) DK (Completed) CZ (Completed) AT (Completed) GR (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000315-24 | Sponsor Protocol Number: 1208182 | Start Date*: 2013-06-18 | ||||||||||||||||
Sponsor Name:CHU SAINT-ETIENNE | ||||||||||||||||||
Full Title: Pharmaco-epidemiology of the treatment of the symptomatic pulmonary embolism among in-patients and 75 years old or more: prospective, multicentric "PEAGE" cohort | ||||||||||||||||||
Medical condition: Symptomatic pulmunory embolism on patients over 75 years | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001397-33 | Sponsor Protocol Number: ARTESIA | Start Date*: 2015-09-15 | |||||||||||
Sponsor Name:Hamilton Health Sciences through the Population Health Research Institute | |||||||||||||
Full Title: APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION | |||||||||||||
Medical condition: Device-detected sub-clinical atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) NL (Ongoing) GB (GB - no longer in EU/EEA) BE (Completed) DE (Ongoing) SE (Completed) ES (Ongoing) DK (Completed) HU (Completed) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001581-15 | Sponsor Protocol Number: CV185-118 | Start Date*: 2013-04-25 | |||||||||||
Sponsor Name:Bristol-Myers Squibb Company | |||||||||||||
Full Title: Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder | |||||||||||||
Medical condition: Thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019791-73 | Sponsor Protocol Number: EFC11405 | Start Date*: 2010-07-22 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrill... | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SE (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) HU (Completed) BE (Prematurely Ended) SK (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) DE (Completed) IT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003168-37 | Sponsor Protocol Number: Thllo | Start Date*: 2019-05-13 |
Sponsor Name:University Tuebingen | ||
Full Title: Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study | ||
Medical condition: Acute respiratory distress syndrome requiring mechanical ventilation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006056-37 | Sponsor Protocol Number: 1160.143 | Start Date*: 2013-09-05 | |||||||||||
Sponsor Name:Hamilton Health Sciences Corporation | |||||||||||||
Full Title: A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardi... | |||||||||||||
Medical condition: MINS (myocardial injury after noncardiac surgery) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) PT (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004350-34 | Sponsor Protocol Number: MK-5348-040 | Start Date*: 2014-10-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | |||||||||||||
Full Title: A Comparative Bioavailability Study of a Tablet versus an Investigational Oral Suspension of Vorapaxar | |||||||||||||
Medical condition: Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004631-31 | Sponsor Protocol Number: REM-PH-416 | Start Date*: 2012-03-13 | |||||||||||||||||||||
Sponsor Name:United Therapeutics Corp. | |||||||||||||||||||||||
Full Title: A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects with Pul... | |||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001709-21 | Sponsor Protocol Number: 2020PI073 | Start Date*: 2020-04-29 | |||||||||||
Sponsor Name:CHRU de Nancy | |||||||||||||
Full Title: Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolis... | |||||||||||||
Medical condition: Prevention of thromboembolic events in hospitalised COVID-19 infected patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004285-19 | Sponsor Protocol Number: NCT04505774 | Start Date*: 2020-11-24 |
Sponsor Name:Fundación para la investigación biomédica del Hospital Universitario La Paz | ||
Full Title: A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Temporarily Halted) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002266-33 | Sponsor Protocol Number: SATURN | Start Date*: 2022-10-10 |
Sponsor Name:BETH ISRAEL DEACONESS MEDICAL CENTER | ||
Full Title: STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS (SATURN) | ||
Medical condition: Intracerebral Hemorrhage (ICH) recurrence | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006238-87 | Sponsor Protocol Number: 4717 | Start Date*: 2010-01-22 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: Improving the safety and efficacy of anticoagulation therapy for thromboembolic disease through vitamin K | ||
Medical condition: Patients will be recruited who are receiving long term warfarin therapy for the treatment or prevention of venous or arterial thrombosis or embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-005887-14 | Sponsor Protocol Number: B1321003 | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:Pfizer Ltd. | |||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS ... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001697-58 | Sponsor Protocol Number: 2128/2021 | Start Date*: 2022-12-20 |
Sponsor Name:Medical University of Vienna | ||
Full Title: An investigation of clinical outcomes and inflammatory response to heparin free extracorporeal membrane oxygenation support during clinical lung transplantation – a prospective double-blind randomi... | ||
Medical condition: Intraoperative extra-corporeal membrane oxygenation during lung transplantation for end-stage lung disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004552-37 | Sponsor Protocol Number: 18CH052 | Start Date*: 2019-05-07 | |||||||||||
Sponsor Name:CHU SAINT-ETIENNE | |||||||||||||
Full Title: Dose Study of Tranexamic Acid in Total Hip Replacement to Reduce Postoperative Hemoglobin Loss. A Phase 2 Randomized Double-blind Monocentric Study | |||||||||||||
Medical condition: Arthropathy of Hip | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
